Package 43063-900-06

{"route": ["ORAL"], "spl_id": "415d1735-9f33-0e91-e063-6394a90a16de", "openfda": {"nui": ["N0000175656", "N0000175462", "N0000009947"], "upc": ["0343063900062"], "unii": ["2T8Q726O95", "4B9XT59T7S"], "rxcui": ["200082"], "spl_set_id": ["ff62c5fc-965d-4534-a571-a4f290cb9d83"], "pharm_class_epc": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["PD-Rx Pharmaceuticals, Inc."]}, "finished": true, "packaging": [{"sample": false, "description": "6 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (43063-900-06)", "package_ndc": "43063-900-06", "marketing_start_date": "20181011"}], "brand_name": "LAMIVUDINE and ZIDOVUDINE", "product_id": "43063-900_415d1735-9f33-0e91-e063-6394a90a16de", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "product_ndc": "43063-900", "generic_name": "LAMIVUDINE and ZIDOVUDINE", "labeler_name": "PD-Rx Pharmaceuticals, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "LAMIVUDINE and ZIDOVUDINE", "active_ingredients": [{"name": "LAMIVUDINE", "strength": "150 mg/1"}, {"name": "ZIDOVUDINE", "strength": "300 mg/1"}], "application_number": "ANDA079124", "marketing_category": "ANDA", "marketing_start_date": "20150918", "listing_expiration_date": "20261231"}